BioMarin Pharmaceuticals BMRN Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's investment proceeds?
- BioMarin Pharmaceuticals (BMRN) reported investment proceeds of $767.28M in Q1 2026.
- How has BioMarin Pharmaceuticals's investment proceeds changed year-over-year?
- BioMarin Pharmaceuticals's investment proceeds increased by 886.2% year-over-year, from $77.8M to $767.28M.
- What is the long-term trend for BioMarin Pharmaceuticals's investment proceeds?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's investment proceeds has grown at a -16.4% compound annual growth rate (CAGR), from $691.05M to $337.8M.
- What does investment proceeds mean?
- Cash received from selling or maturing investment securities.
- How do you interpret investment proceeds?
- An increase suggests the company is liquidating assets to generate cash, while a decrease indicates a strategy of holding securities to maturity or reinvesting.
- How does investment proceeds compare across companies?
- Common in biotech firms managing cash reserves; peers often show varying levels based on treasury management strategies.